Midazolam (Surgical — Anxiolysis/Sedation)
Brand names: Hypnovel, Buccolam (buccal)
Midazolam is a short-acting intravenous benzodiazepine used surgically for premedication, conscious sedation for procedures, and the induction or maintenance of sedation in anaesthesia and critical care.
Adult dose
Paediatric dose
Dose adjustments
In severe renal impairment (creatinine clearance below 30 ml/min) sedation may be more pronounced and prolonged, possibly with clinically relevant respiratory and cardiovascular depression — dose carefully and titrate to effect. After prolonged infusion in ICU patients with renal failure the mean duration of sedative effect was considerably increased, most likely due to accumulation of 1'-hydroxy-midazolam glucuronide.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to midazolam, benzodiazepines or to any of the excipients
- Use for conscious sedation in patients with severe respiratory failure or acute respiratory depression
Side effects
- Respiratory depression, apnoea, respiratory arrest, dyspnoea, laryngospasm, hiccups — severe cardiorespiratory events are more likely when the injection is given too rapidly or at high dosage
- Cardiac arrest, bradycardia, Kounis syndrome; hypotension, vasodilatation, thrombophlebitis, thrombosis
- Sedation (prolonged and postoperative), decreased alertness, somnolence, headache, dizziness, ataxia, anterograde amnesia (duration directly related to the dose); convulsions reported in premature infants and neonates
- Paradoxical reactions — restlessness, agitation, irritability, nervousness, hostility, anger, aggressiveness, anxiety, nightmares, hallucinations, inappropriate behaviour (reported particularly in children and the elderly); confusional state, disorientation
- Physical dependence and withdrawal syndrome after prolonged IV administration; hypersensitivity, angioedema, anaphylactic shock; nausea, vomiting; injection site erythema and pain; falls and fractures
Interactions
- NOTE: eMC §4.5 was not captured in this bundle — the interactions below are from the US labelling and must be checked against the UK SPC §4.5 before publication
- Opioids — concomitant use with benzodiazepines increases the risk of respiratory depression; limit the dose and duration of concomitant use and monitor closely
- Other CNS depressants — the sedative effect of IV midazolam is accentuated by narcotics (e.g. morphine, pethidine/meperidine, fentanyl), secobarbital and droperidol; adjust the midazolam dose accordingly
- CYP3A4 inhibitors — caution when given with cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole
Clinical monograph
How it works
It potentiates the inhibitory neurotransmitter GABA at the GABA-A receptor, producing sedation, anxiolysis, anterograde amnesia and muscle relaxation.
Prescribing in practice
- Titrate slowly to effect with full resuscitation facilities and continuous monitoring, because midazolam causes dose-dependent respiratory depression and hypotension — risk is markedly increased by concomitant opioids and in the elderly, who need substantially reduced doses.
- Have the reversal agent flumazenil immediately available, and reduce dose in hepatic impairment, debilitated patients and where other CNS depressants are used.
- Allow adequate time for each increment to take effect before redosing, as delayed onset can lead to inadvertent oversedation.
Monitoring
Monitor respiratory rate, oxygen saturation, blood pressure and conscious/sedation level continuously throughout and during recovery.
Counselling the patient
- Explain it is a sedative given by injection to relax you, and that you may not remember parts of the procedure.
- Do not drive, operate machinery, drink alcohol or make important decisions for the rest of the day after sedation, and arrange for someone to accompany you home.
Evidence & guidelines
Midazolam is a standard agent for procedural sedation and anaesthetic premedication; UK safe-sedation guidance and the SPC stress titration, monitoring, dose reduction in the elderly and flumazenil availability.
Reference: MHRA Drug Safety Update 2016 (opioid + benzo); RCoA Regional Anaesthesia Guidelines; NICE NG180 (Sedation in Adults); MHRA SPC Hypnovel; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Richmond Agitation-Sedation Scale (RASS) · Sedation Assessment
- Confusion Assessment Method for ICU (CAM-ICU) · Delirium Assessment
- Ramsay Sedation Scale · Sedation
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- ASA Physical Status Classification · Perioperative Risk
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH